A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix and placebo, for the treatment of actinic keratosis with photodynamic therapy.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aminolevulinic acid (Primary) ; Methyl aminolevulinate
Indications Actinic keratosis
Focus Registrational; Therapeutic Use
Sponsors Biofrontera AG

Most Recent Events

11 Feb 2016 Results from this trial will be presented at the 14th Annual South Beach Symposium, according to a Biofrontera media release.
03 Jul 2012 Additional trial location (France) added as reported by European Clinical Trials Database record.
06 Oct 2011 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight